NASDAQ:IFRX - Inflarx Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $45.35 -0.81 (-1.75 %) (As of 03/21/2019 04:00 PM ET)Previous Close$46.16Today's Range$44.45 - $46.1152-Week Range$20.31 - $51.33Volume178,200 shsAverage Volume117,135 shsMarket Capitalization$1.06 billionP/E Ratio-15.40Dividend YieldN/ABeta-0.84 ProfileDiscussionAnalyst RatingsChartEarningsInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. It also develops IFX-2 for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. Receive IFRX News and Ratings via Email Sign-up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IFRX Previous Symbol CUSIPN/A CIKN/A Webwww.inflarx.de Phone49-36-4150-8180Debt Debt-to-Equity RatioN/A Current Ratio18.71 Quick Ratio18.71Price-To-Earnings Trailing P/E Ratio-15.40 Forward P/E Ratio-34.10 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.77 per share Price / Book7.86Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares23,410,000Market Cap$1.06 billion Next Earnings Date4/4/2019 (Estimated) OptionableNot Optionable Inflarx (NASDAQ:IFRX) Frequently Asked Questions What is Inflarx's stock symbol? Inflarx trades on the NASDAQ under the ticker symbol "IFRX." How were Inflarx's earnings last quarter? Inflarx NV (NASDAQ:IFRX) issued its quarterly earnings results on Thursday, August, 9th. The company reported ($0.12) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.36) by $0.24. View Inflarx's Earnings History. When is Inflarx's next earnings date? Inflarx is scheduled to release their next quarterly earnings announcement on Thursday, April 4th 2019. View Earnings Estimates for Inflarx. What price target have analysts set for IFRX? 8 brokers have issued 1 year price targets for Inflarx's shares. Their predictions range from $42.00 to $65.00. On average, they expect Inflarx's share price to reach $53.1250 in the next twelve months. This suggests a possible upside of 17.1% from the stock's current price. View Analyst Price Targets for Inflarx. What is the consensus analysts' recommendation for Inflarx? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inflarx in the last year. There are currently 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inflarx. Has Inflarx been receiving favorable news coverage? News stories about IFRX stock have trended very negative recently, according to InfoTrie. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Inflarx earned a media sentiment score of -3.6 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. Who are some of Inflarx's key competitors? Some companies that are related to Inflarx include Taro Pharmaceutical Industries (TARO), TESARO (TSRO), HUTCHISON CHINA/S (HCM), Agios Pharmaceuticals (AGIO), ACADIA Pharmaceuticals (ACAD), Blueprint Medicines (BPMC), Evotec (EVTCY), Ultragenyx Pharmaceutical (RARE), Intercept Pharmaceuticals (ICPT), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT), Reata Pharmaceuticals (RETA), Akcea Therapeutics (AKCA), Mirati Therapeutics (MRTX) and Ligand Pharmaceuticals (LGND). What other stocks do shareholders of Inflarx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inflarx investors own include Global Blood Therapeutics (GBT), Incyte (INCY), Exelixis (EXEL), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), AbbVie (ABBV), Atara Biotherapeutics (ATRA), Agilent Technologies (A), Madrigal Pharmaceuticals (MDGL) and Micron Technology (MU). Who are Inflarx's key executives? Inflarx's management team includes the folowing people: Dr. Niels C. Riedemann M.D., Ph.D., Co-Founder, CEO & Exec. Director (Age 47)Prof. Renfeng Guo, Co-Founder, Chief Scientific Officer & Exec. Director (Age 49)Mr. Arnd Christ, Chief Financial Officer (Age 53)Mr. Jason M. Marks, Chief Legal Officer, Gen. Counsel & Corp. Sec.Mr. Jordan Silverstein, Head of Corp. Devel. & Strategy When did Inflarx IPO? (IFRX) raised $100 million in an initial public offering (IPO) on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. Who are Inflarx's major shareholders? Inflarx's stock is owned by a number of of retail and institutional investors. Top institutional investors include RA Capital Management LLC (8.91%), BlackRock Inc. (5.39%), Polar Capital LLP (0.61%), Emory University (0.35%), Millennium Management LLC (0.31%) and Essex Investment Management Co. LLC (0.09%). Which institutional investors are selling Inflarx stock? IFRX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Geode Capital Management LLC, Northern Trust Corp, Emory University and D. E. Shaw & Co. Inc.. Which institutional investors are buying Inflarx stock? IFRX stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Polar Capital LLP, Essex Investment Management Co. LLC, Bank of America Corp DE, Paloma Partners Management Co and Millennium Management LLC. How do I buy shares of Inflarx? Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Inflarx's stock price today? One share of IFRX stock can currently be purchased for approximately $45.35. How big of a company is Inflarx? Inflarx has a market capitalization of $1.06 billion. The company earns $-27,390,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. What is Inflarx's official website? The official website for Inflarx is http://www.inflarx.de. How can I contact Inflarx? Inflarx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 49-36-4150-8180. MarketBeat Community Rating for Inflarx (NASDAQ IFRX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 110 (Vote Outperform)Underperform Votes: 130 (Vote Underperform)Total Votes: 240MarketBeat's community ratings are surveys of what our community members think about Inflarx and other stocks. Vote "Outperform" if you believe IFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IFRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/21/2019 by MarketBeat.com StaffFeatured Article: What is the S&P 500 Index?